Health Care Delivery

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations.

Prior authorization remains a major health care barrier, causing delays and frustrations for insured adults seeking necessary treatments.

Addressing poor medication adherence should be a top priority in health plans to ensure short- and long-term benefits in health outcomes and financial stability.

Explore critical health equity issues as barriers to care access and health disparities that impact treatment for allergic rhinitis and childhood vaccinations.

This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.

The upcoming price negotiations are the third cycle since the Inflation Reduction Act was passed in 2022.

AAP’s 2026 immunization schedule continues protection against 18 diseases as the CDC reduces its recommendations to 11.

Experts raise concerns that CDC childhood immunization changes could reduce vaccine uptake and weaken trust in public health guidance.

Minnesota physicians warn ICE activity in hospitals and clinics is deterring care, undermining patient safety, and worsening health outcomes.

With the CDC’s decision to roll back recommendations to vaccinate for several conditions, questions have arisen as to what that may mean in the US.

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

Ongoing phase 3 trials target improved therapies for hematologic malignancies, focusing on CLL, multiple myeloma, and pediatric leukemia outcomes.

Patients with allergic rhinitis face prolonged symptoms and inadequate treatment, highlighting a need for better awareness and access to allergen immunotherapy.

Research reveals that socioeconomic status significantly impacts survival rates in young adults with metastatic colorectal cancer, emphasizing the need for health equity initiatives.

Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.

A multistakeholder study explores how law enforcement presence in EDs affects survivors of violence and outlines trauma-informed, patient-centered policy solutions.

Socioeconomic and demographic factors influenced amputation and recurrence rates in upper extremity soft tissue sarcoma.

A study shows that PF impacts sexual activity physically and emotionally, emphasizing the need for holistic patient care and quality-of-life assessments.

Oral nalbuphine significantly reduced cough frequency and severity in idiopathic pulmonary fibrosis (IPF), with patients seeing greater benefit at higher doses.

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.

Sleep-focused TNX-102 SL delivered significant benefits in a phase 3 fibromyalgia study.

Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis biomarkers, supporting disease-modifying potential in IPF.

The decline in primary care providers threatens Medicare FFS patients' access to new visits, highlighting urgent needs for policy reform and workforce solutions.